Kymera Therapeutics, Inc. Common Stock (KYMR) Stock
NASDAQ · KYMR
111.38
Fundamentals
Market cap
$9.31B
Price / Earnings ratio
-32.1x
Price / Sales ratio
91.7x
Price / Book ratio
6.4x
Return on assets
-22.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
NeutralKYMRSeptember 4, 2026
Zacks Investment ResearchNeutral
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR

Zacks Investment Research
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
NeutralKYMRSeptember 3, 2026
Zacks Investment ResearchNeutral
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR

Zacks Investment Research
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
NeutralKYMRAugust 6, 2026
Zacks Investment ResearchNeutral
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR

MarketBeat
Kymera Therapeutics Q2 Earnings Call Highlights
NeutralKYMRAugust 5, 2026
MarketBeatNeutral
Kymera Therapeutics Q2 Earnings Call Highlights
KYMR
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral2
Buy7
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
47M31M16M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
2B1B690M0
Revenue to Profit
2025$39.2M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-311.4M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
NeutralKYMRSeptember 4, 2026
Zacks Investment ResearchNeutral
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR

Zacks Investment Research
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
NeutralKYMRSeptember 3, 2026
Zacks Investment ResearchNeutral
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR

Zacks Investment Research
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
NeutralKYMRAugust 6, 2026
Zacks Investment ResearchNeutral
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR

MarketBeat
Kymera Therapeutics Q2 Earnings Call Highlights
NeutralKYMRAugust 5, 2026
MarketBeatNeutral
Kymera Therapeutics Q2 Earnings Call Highlights
KYMR

Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
NeutralKYMRAugust 5, 2026
Zacks Investment ResearchNeutral
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
KYMR

Zacks Investment Research
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
NeutralKYMRJuly 24, 2026
Zacks Investment ResearchNeutral
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
KYMR

The Motley Fool
Kymera's CEO Sold $6 Million in Stock After a 170% Run
NeutralKYMRJuly 12, 2026
The Motley FoolNeutral
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMR

Zacks Investment Research
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
NeutralKYMRJuly 1, 2026
Zacks Investment ResearchNeutral
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR

The Motley Fool
Why Kymera Therapeutics Stock Popped This Week
NeutralKYMRJune 26, 2026
The Motley FoolNeutral
Why Kymera Therapeutics Stock Popped This Week
KYMR

Zacks Investment Research
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
NeutralKYMRJune 26, 2026
Zacks Investment ResearchNeutral
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR
About Kymera Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees273
CEODr. Nello Mainolfi M.D., Ph.D.
IPO DateAug 21, 2020
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 1979 |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer | — |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Corporate Secretary | 1974 |
| Dr. Jared A. Gollob M.D. | Advisor | 1965 |
| Mr. Noah Goodman M.B.A. | Chief Business Officer | 1987 |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations | — |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer | 1959 |
| Mr. Brian Albarran M.B.A., Ph.D. | SVP of Corporate Strategy | — |
| Dr. Juliet Williams B.A Ph.D. | Head of Research | — |
| Dr. Jeremy G. Chadwick Ph.D. | Advisor | 1963 |
Fundamentals
Valuation
Market cap$9.31B
Price-to-sales ratio91.71
Price-to-book value6.38
Price-earnings ratio-32.10
Return on Equity-25.00%
Return on Sales-611.00%
Return on Assets-22.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.25
Income Statement
Average volume733,833
EBITDA$-306.36M
1 year high (52w)$130.05
1 year low (52w)$51.47
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
11 Wall Street Analyst Ratings
BUY
82% Buy
18% Hold
0% Sell
Target price
$142.20
Est return
27.82%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.5 | -2.2 | -12.0 | +18.3 | ||||||||
| 2022 | -35.1 | -11.2 | +9.8 | -24.7 | -56.4 | +39.3 | +4.4 | +31.6 | -22.5 | +44.8 | -3.2 | -13.1 |
| 2023 | +50.5 | -14.2 | -7.6 | +6.2 | -6.5 | -21.8 | -7.2 | -12.0 | -30.0 | -14.0 | +79.7 | +22.6 |
| 2024 | +29.3 | +30.7 | -7.6 | -14.7 | -11.4 | -5.4 | +49.3 | +8.7 | +2.2 | -0.9 | +0.8 | -15.7 |
| 2025 | -3.2 | -18.6 | -9.3 | +35.8 | -14.2 | +1.2 | -1.6 | -4.1 | +39.1 | +13.1 | +13.7 | +16.4 |
| 2026 | -0.1 | +20.8 | -7.6 | -4.5 | +0.9 | +46.1 | -9.5 | +18.4 | -6.0 |



